Emerging data suggest Retatrutide , a dual agonist targeting both the gut-brain axis and glucose-dependent insulinotropic polypeptide , may offer a significant advancement for body loss . Preliminary https://getretatrutideaustralia.com/blog/retatrutide-vs-tirzepatide-semaglutide